Non-Small Cell Cancer

More than one-third of adults with previously untreated stage III non-small cell lung cancer exhibited a pathologic complete response after receiving perioperative nivolumab plus chemotherapy, results of a randomized phase 2 trial showed.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the randomized phase 3 IND.227/KEYNOTE-483 trial.

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

The addition of sitravatinib to nivolumab failed to extend OS, when compared with docetaxel, among certain patients with nonsquamous non-small cell lung cancer, according to topline data from the agent’s manufacturer.

A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.

Neoadjuvant nivolumab plus platinum-based chemotherapy conferred sustained clinical benefit for patients with resectable non-small cell lung cancer, 3-year follow-up results of the phase 3 CheckMate -816 trial showed.

The FDA approved capmatinib for treatment of certain adults with metastatic non-small cell lung cancer.

CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.